Adverse events693

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 693

Download this page as JSON

Type	Event	Organ system	Group	Affected	At risk
other	Upper Respiratory Tract Infection	Infections and infestations	Randomized Phase: Brigatinib 90 mg QD/180 QD	18	136
other	Upper Respiratory Tract Infection	Infections and infestations	Randomized Phase: Crizotinib 250 mg BID	12	137
other	Upper Respiratory Tract Infection	Infections and infestations	Crossover Phase: Brigatinib 90 mg QD/180 mg QD	6	65
other	Nasopharyngitis	Infections and infestations	Randomized Phase: Brigatinib 90 mg QD/180 QD	12	136
other	Nasopharyngitis	Infections and infestations	Randomized Phase: Crizotinib 250 mg BID	15	137
other	Nasopharyngitis	Infections and infestations	Crossover Phase: Brigatinib 90 mg QD/180 mg QD	5	65
other	Urinary Tract Infection	Infections and infestations	Randomized Phase: Brigatinib 90 mg QD/180 QD	10	136
other	Urinary Tract Infection	Infections and infestations	Randomized Phase: Crizotinib 250 mg BID	11	137
other	Urinary Tract Infection	Infections and infestations	Crossover Phase: Brigatinib 90 mg QD/180 mg QD	5	65
other	Pneumonia	Infections and infestations	Randomized Phase: Brigatinib 90 mg QD/180 QD	10	136
other	Pneumonia	Infections and infestations	Randomized Phase: Crizotinib 250 mg BID	5	137
other	Pneumonia	Infections and infestations	Crossover Phase: Brigatinib 90 mg QD/180 mg QD	6	65
other	Respiratory Tract Infection	Infections and infestations	Randomized Phase: Brigatinib 90 mg QD/180 QD	7	136
other	Respiratory Tract Infection	Infections and infestations	Randomized Phase: Crizotinib 250 mg BID	3	137
other	Respiratory Tract Infection	Infections and infestations	Crossover Phase: Brigatinib 90 mg QD/180 mg QD	0	65
other	Anaemia	Blood and lymphatic system disorders	Randomized Phase: Brigatinib 90 mg QD/180 QD	12	136
other	Anaemia	Blood and lymphatic system disorders	Randomized Phase: Crizotinib 250 mg BID	8	137
other	Anaemia	Blood and lymphatic system disorders	Crossover Phase: Brigatinib 90 mg QD/180 mg QD	5	65
other	Decreased Appetite	Metabolism and nutrition disorders	Randomized Phase: Brigatinib 90 mg QD/180 QD	16	136
other	Decreased Appetite	Metabolism and nutrition disorders	Randomized Phase: Crizotinib 250 mg BID	28	137

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02737501/events

API reference For AI assistants

Adverse events693

Sources 3

Read this list from software.